Clinical Trials Logo

Clinical Trial Summary

Background : Surgery is needed in order to flatten and position a detached retina onto the choroid, to allow sealing of the tears and to prevent or reverse vision loss. In case of complex retinal detachment vitrectomies followed by ocular endotamponade - non-solid implants used in ophthalmology - is the most common treatment. Despite several options used by surgeons were not entirely satisfactory, no innovation were marketed in the ocular endotamponade field since decades. Purpose : Regarding comparative physico-chemical properties of medium-chain triglycerides (MCT) with current tamponading agents (silicone oil or gases), it will be proposed to evaluate the MCT as an ocular endotamponade product.


Clinical Trial Description

Previously a nonclinical study has provide an assessment of the safety and the local tissue effects of the Medium-Chain Triglyceride (MCT) tamponade agent manufactured by the company Arcadophta : There were no histopathologic findings or irritation events that were directly attributable to the MCT device. In conclusion, under the conditions of the study, the MCT device did not induce any adverse local tissue effects compared to a control tamponading agent silicone oil. The present clinical study is the first use of MCT tamponade agent which assigns human participants. The MCT tamponade agent studied is manufactured by the company Arcadophta and designed as a Class IIb medical device in Europe. Tamponment efficacy and human eye safety of the device are supported by a flatten retina observation and a healthy eye fundus exam respectively as long as the tamponade agent is present. The patient treatment is the classical surgical procedure which is used for retinal detachment with silicone oil. - Vitrectomy, then flattened retina, and finally MCT injection in place of the vitreous. - MCT ablation after 4 to 6 weeks (after effective retinopexy) The patient follow-up begins 4 days before treatment , then 3 time-points exams are performed before MCT ablation and 4 time-points exams are performed after MCT ablation for a total patient follow-up duration of 6 months. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03855462
Study type Interventional
Source University Hospital, Toulouse
Contact
Status Completed
Phase N/A
Start date December 17, 2018
Completion date January 25, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT05414994 - Assessment of the Ocular Microbiome in Health and Disease
Completed NCT04387292 - Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic N/A
Terminated NCT05494229 - Autologous Blood for Full-thickness Macular Hole N/A
Completed NCT05494242 - Single Superior ILM/ERM Flap for the FTMH. N/A
Completed NCT04982484 - Reading Speed Improvements in Wet-AMD Patients After Ranibizumab Treatment
Completed NCT04683055 - Phaco-Trabeculotomy Vs Phaco-Trabeculectomy N/A
Recruiting NCT06367517 - Tocilizumab in Corticosteroid-Resistant Graves' Orbitopathy (Thyroid Eye Disease)
Completed NCT03766737 - Validation of the Utility of an Intelligent Visual Acuity Diagnostic System for Children N/A
Recruiting NCT04460001 - Injection of Ranibizumab Versus Combination of Ranibizumab and Triamcinolone Acetate for (CRVO) Phase 2/Phase 3
Completed NCT04917562 - Refractive Transepithelial Photo-keratectomy (T-PKR) in High Myopia
Completed NCT04771039 - Ocular Manifestations of Inflammatory Bowel Disease
Completed NCT03492242 - Immune CHeckpoint Inhibitors Monitoring of Adverse Drug ReAction
Withdrawn NCT04579458 - Assessment of COVID-19 in Tearfilm
Recruiting NCT06293586 - Comparison Between Peribulbar And Sub-tenon Blocks on Oculocardiac Reflex (OCR) During Pediatric Strabismus Surgery N/A
Recruiting NCT06102265 - Effect Of Reusing the Operative Supplies On Cataract Surgery and Climate Change
Recruiting NCT03611387 - Artificial Intelligence Screening on Patients With Primary Angle Closure Glaucoma
Completed NCT03499145 - Validation of the Utility of Ophthalmology Intelligent Diagnostic System